Article Text

Download PDFPDF
Flow cytometric DNA analysis in gynecological oncology
  1. P. A. VAN DAM*,
  2. J. V. WATSON,
  3. D. G. LOWE and
  4. J. H. SHEPHERD*
  1. *The joint Gynaecological Oncology Unit, Departments of Gynaecology, Saint Bartholomew's and the Royal Marsden Hospitals, London
  2. The Medical Research Council Clinical Oncology Unit, Cambridge
  3. The Department of Pathology, Saint Bartholomew's Hospital, London, UK
  1. Address for correspondence: Dr P. A. van Dam, Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, Antwerp University Hospital (UZA), Wilrijkstraat 10, B-2520 Edegem, Belgium.


The relevance of flow cytometric DNA analysis in neoplasia of the female genital tract is reviewed. The virtues and limitations of the technique are discussed. There is good evidence, mainly from retrospective studies, that DNA ploidy and/or the tumor S-phase fraction are valuable prognostic indicators in patients with carcinoma of the ovary and endometrium. Further prospective studies are needed, however, to establish the precise value of flow cytometric DNA analysis before it can be used safely for stratification of therapeutic regimes.

  • cervix
  • DNA analysis
  • endometrium
  • flow cytometry
  • ovary

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.